Hydroxytyrosol.

Oleuropein is a secoiridoid ester that is hydrolysed by gut esterases and colonic bacteria to release hydroxytyrosol as its active phenol. Supplying both gives an immediate free phenol plus a slower released reservoir from the same chemistry.

EPA and DHA carry five and six double bonds and oxidise readily both in the container and after absorption. Hydroxytyrosol is an ortho-diphenol that donates hydrogen to the propagating lipid radical, which is why olive phenolics are used as the antioxidant in marine oil formulations.

Alpha-tocopherol is the front-line chain breaker inside the lipid membrane and is consumed as it works. Hydroxytyrosol partitions to the lipid and water interface and regenerates or spares tocopherol, so the pair lasts longer than either alone.

When hydroxytyrosol quenches a radical it becomes a phenoxyl radical itself. Ascorbate in the aqueous phase donates an electron back and returns it to the active phenol, the same recycling relationship ascorbate has with tocopherol.

Ubiquinol sits in the same membrane compartment and takes part in the recycling network that keeps tocopherol reduced. Adding an olive polyphenol to that network spreads the radical load across more carriers instead of exhausting one.

Both phenolics act as mild electrophilic stressors that release Nrf2 from Keap1 and raise transcription of the body's own antioxidant enzymes. That is an indirect and durable effect that adds to the direct radical scavenging each does on its own.

Hydroxytyrosol carries an ortho-dihydroxy catechol group that donates hydrogen atoms readily, forming a resonance-stabilised semiquinone. Dihydrolipoic acid, the reduced form of alpha-lipoic acid, regenerates several oxidised antioxidants and sits upstream in the same recycling chain. The interaction is mechanistic and biochemically settled rather than measured as a clinical outcome for the pair. No combination trial in people has been identified.

The catechol of hydroxytyrosol can oxidise to an ortho-quinone, and glutathione is the cell's principal thiol for conjugating quinones. That reaction is standard xenobiotic biochemistry and describes how the phenol is handled rather than a benefit. Formulating the two together does not change what either does in the gut. Read it as mechanistic context, not as a clinical pairing.

N-acetylcysteine supplies cysteine, the rate-limiting substrate for glutathione synthesis, which is settled metabolic biochemistry. Because glutathione handles the quinone forms of catechols such as hydroxytyrosol, adequate cysteine supply supports the normal disposal route. This is upstream substrate logic, not a measured additive effect. No trial has tested the two together.

Both hydroxytyrosol and quercetin are cleared largely by intestinal and hepatic sulfotransferase and UDP-glucuronosyltransferase activity. Polyphenols taken together at high doses compete for those same conjugating enzymes, which is well described for the class. The practical direction is altered exposure of one or both, not enhanced potency. The size of the effect in a finished supplement has not been quantified.

Astaxanthin sits within the lipid bilayer and spans it, while hydroxytyrosol is small and amphipathic and acts at the aqueous interface. Antioxidants at different depths of a membrane cover different sites of radical attack, which is standard membrane chemistry. The pairing is mechanistically coherent in vitro. It has not been tested as a combination in people.

Selenium is the catalytic centre of glutathione peroxidase enzymes, a settled cofactor relationship. Those enzymes handle peroxides that a phenolic antioxidant such as hydroxytyrosol does not reduce directly. Adequate selenium status therefore supports a different arm of normal antioxidant defence. The relationship is complementary rather than a measured combination effect.

Tocotrienols terminate lipid peroxidation chains inside the membrane, leaving a chromanoxyl radical that must be reduced by an aqueous-phase donor. Small catechol phenols such as hydroxytyrosol can perform that kind of interfacial reduction in model systems. Both constituents also co-occur in plant lipid sources. The evidence is mechanistic and in vitro rather than clinical.

Hydroxytyrosol is markedly more water soluble than the triglycerides it is usually sold alongside, so it separates out of a plain oil softgel. Lecithin phospholipids form mixed micelles that hold the phenol dispersed in the lipid phase. This is a routine emulsification decision in manufacturing. It affects product uniformity, not a physiological outcome.

Medium-chain triglycerides are liquid at room temperature and stable against oxidation, which makes them a common carrier for olive-derived concentrates in softgels. Hydroxytyrosol itself is amphipathic, so a lecithin or emulsifier is usually needed alongside the oil. The role of MCT here is a vehicle and stability decision. It is not evidence of improved absorption in people.

Olive fruit concentrates carry carotenoids alongside phenolics, and finished products sometimes add beta-carotene to reflect that profile. The two act in different phases of a formulation, lipid and interfacial. No interaction between them has been measured. The pairing is compositional.

EGCG and hydroxytyrosol both present catechol groups that are heavily sulfated and glucuronidated in the intestinal wall. Loading two catechol polyphenols at once saturates a shared clearance route, which is a documented class behaviour. The consequence is changed exposure, which could go either way and has not been quantified for this pair. Anyone stacking multiple high-dose polyphenols should regard total load as the variable, not each ingredient alone.

Ascorbate reduces phenoxyl radicals back to the parent phenol, a reaction that is textbook antioxidant chemistry and is not specific to any one phenol. Hydroxytyrosol forms such a radical when it donates a hydrogen atom. Ascorbate can therefore regenerate it in solution. Whether this translates into a measurable effect in a person taking a supplement has not been shown.